Loxo Oncology (LOXO) Tops Q1 EPS by 60c, Beats on Revenues
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/26/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mail
Get Alerts LOXO Hot Sheet
Join SI Premium – FREE
Loxo Oncology (NASDAQ: LOXO) reported Q1 EPS of ($0.12), $0.60 better than the analyst estimate of ($0.72). Revenue for the quarter came in at $38.43 million versus the consensus estimate of $16.46 million.
For earnings history and earnings-related data on Loxo Oncology (LOXO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
- Barclays Starts Life Time Group Holdings Inc (LTH) at Overweight
- Citizens Starts Blackstone Secured Lending Fund (BXSL) at Market Perform
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
